The Diplomat in Spain
  • Frontpage
  • News
    • Spain
    • World
    • The world in Spain
    • Diplomatic Breakfast
    • Diplomacy with a history
    • The bag
    • Social life
    • Appointments
  • Tribune
  • VIP Club
  • Embassies
    • Embassies Directory
    • Protocol
    • International legislation
  • Discover Spain
  • UNWTO News
  • Leisure
    • Culture & Art
    • Entertainment
    • Movies
  • es Español
  • en English
  • Account
No Result
View All Result
  • Frontpage
  • News
    • Spain
    • World
    • The world in Spain
    • Diplomatic Breakfast
    • Diplomacy with a history
    • The bag
    • Social life
    • Appointments
  • Tribune
  • VIP Club
  • Embassies
    • Embassies Directory
    • Protocol
    • International legislation
  • Discover Spain
  • UNWTO News
  • Leisure
    • Culture & Art
    • Entertainment
    • Movies
No Result
View All Result
The Diplomat in Spain
No Result
View All Result

Brussels signs purchase of 250 million doses of Spain’s Hipra Covid vaccine

August 3, 2022
in In brief
The Diplomat

 

The European Commission yesterday announced the signing of a joint procurement contract with Spanish pharmaceutical company Hipra Human Health to secure the supply of 250 million doses of its protein vaccine against the coronavirus ‘Hipra’.

 

A total of 14 Member States will participate in this joint procurement, the value of which has not been disclosed by Brussels. Under this agreement, 250 million vials of this protein vaccine will be supplied and will be developed as a booster dose for previously immunised people over the age of 16.

 

With COVID infections on the rise in Europe, “we must ensure maximum preparedness as we approach the autumn and winter months,” Health Commissioner Stella Kyriakides said in a statement.

 

The Spanish vaccine is currently under evaluation by the European Medicines Agency (EMA), so if it receives marketing authorisation, participating countries will be able to purchase the vaccine through this existing contract.

 

The joint vaccine purchase agreement with Hipra complements previously signed contracts with AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica, BioNtech-Pfizer, Moderna, Novavax and Valneva, securing some 4.2 billion doses for the EU market as part of the COVID vaccination strategy.

 

Participating countries could decide to donate the vaccines to low and middle-income countries or redirect them to other European countries.

 

Prime Minister Pedro Sánchez yesterday welcomed the signing of the contract, saying it is “very good news” and that it “demonstrates the strength of innovation and the pharmaceutical industry in our country, and also the public-private collaboration that we have developed with this Catalan and Spanish industry, which has borne fruit”.

 

 

ShareTweetSend
Previous Post

Government approves Nieves Blanco's appointment as ambassador to Lithuania

Next Post

Some 7.5 million tourists visited Spain in June, three times more than in 2021

The bag

The future of the Spanish Presidency worries European ambassadors

The bringing forward of the general elections to 23 July has caused surprise, not only at the national level, but also in European embassies

More bags>

Hemeroteca

Receive our newsletter

We use MailChimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to MailChimp for processing. Learn more about MailChimp's privacy practices here.

  • Contacto
  • ¿Quiénes somos?
  • Aviso legal y Propiedad intelectual

© The Diplomat in Spain. All rights reserved.

  • English
  • Español (Spanish)
Account
  • Frontpage
  • News
    • Spain
    • World
    • The world in Spain
    • Diplomatic Breakfast
    • Diplomacy with a history
    • The bag
    • Social life
    • Appointments
  • Tribune
  • VIP Club
  • Embassies
    • Embassies Directory
    • Protocol
    • International legislation
  • Discover Spain
  • UNWTO News
  • Leisure
    • Culture & Art
    • Entertainment
    • Movies

© The Diplomat in Spain. All rights reserved.

Tanto nuestros partners como nosotros utilizamos cookies en nuestro sitio web para personalizar contenido y publicidad o analizar nuestro tráfico. Haciendo click consientes el uso de esta tecnología en nuestra web. Saber más